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Circulating plasma levels of the oncofetal antigen, car-
cinoembryonic antigen, were examined in 18 patients 
with various forms of epidermolysis bullosa. Carcinoem-
bryonic antigen was markedly elevated in the plasma of 
4 of 6 patients with recessive dystrophic epidermolysis 
bullosa and in 1 of 2 patients with recessive epider-
molysis bullosa letalis. In contrast, patients with domi-
nantly inherited forms of the disease, dominant epider-
molysis· bullosa simplex and dominant dystrophic epi-
dermolysis bullosa, had normal levels of antigen. In the 
recessive patients, the plasma levels of carcinoem-
bryonic antigen appeared to correlate with the severity 
of cutaneous involvement. Alternatively, it is possible 
that expression of carcinoembryonic antigen is geneti-
cally linked to certain forms of recessive epidermolysis 
bullosa or is part of a pleiotropic effect of the gene coding 
for the disease. 
Carcinoembryonic antigen (CEA) is a high· molecular weight 
glycoprotein produced primarily by tumors of endodermal ori-
gin and by fetal gastrointestinal tissue [1]. Although circulating 
levels of this oncofetal antigen have been used as a marker for 
gastrointestinal tract malignancy [2, 3], CEA and/or CEA cross-
reactive antigens have been found in a variety of nonendoder-
mally derived tumors as well as in certain chronic inflammatory 
or reparative processes and in normal tissues and fluids [4-7). 
In epidermolysis bullosa (EB), a group of genetic diseases 
characterized by blistering following minor trauma to the skin, 
patients frequently have large eroded or ulcerated areas on the 
skin. In addition, patients with the severe forms of EB, partic-
ularly recessive dystrophic EB, may develop epidermoid carci-
nomas in these areas of chronic cutaneous ulceration [8]. For 
these reasons, the present study was designed to assess whether 
patients with EB express CEA, whether the expression of CEA 
is specific for any type of EB and, if so, whether circulating 
levels of CEA correlate with disease activity. 
MATERIALS AND METHODS 
Patient Sources 
A total of 18 patients with EB were the subjects of this study. All 
patients were examined by 2 of us (N.B.E. and E.A.B.) and classified 
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based on clinical, genetic and histologic findings (including diagnostic 
electron microscopy), as described previously [9]. Controls consisted. of 
plasma from 38 normal, nonsmoking adults and from 54 patients WIth 
nondermatologic diseases (rheumatoid arthritis or renal disease). As a 
further control, plasma CEA levels were determined in 21 patients with 
a variety of dermatologic diseases. 
Radioimmunoassay for CEA 
Circulating plasma levels of CEA were determined using the Hansen 
z-gel technique [2, 4]. Briefly. CEA was extracted from the plasma usmg 
perchloric acid, as described by Hansen et al [4], and allowed to react 
with appropriately diluted CEA antiserum in the presence of 125I_CEA. 
Antibody bound 125I_CEA was then separated from free 125I_CEA with 
zirconyl phosphate gel and the levels of bound 125I_CEA determined in 
a gamma scintillation spectrometer. The amount of CEA present in the 
sample was determined from a standard inhibition curve [4]. 
RESULTS 
The circulating CEA levels from 2 of the control groups-the 
normal, nonsmoking adults and the patients with nonderma-
tologic disorders-ranged from 0 to 5.0 ng/rnl (Table I) . As an 
additional control, since most clinical studies of CEA have not 
examined dermatologic disorders, it seemed essential to deter-
mine baseline levels in this group of patients. As shown in Table 
I, the 21 patients with a wide variety of nonheritable dermato-
logic disorders had a mean value of 4.6 ± 0.4 ng/rnl (mean ± 
SE) of CEA (range, 0.8-B.B ng/rnl). Nine of the 21 patients had 
circulating CEA levels in excess of 5.0 ng/rnl. Of these, 4 
patients had mycosis fungo ides or Sezary syndrome with values 
ranging from 6.0 to 8.8 ng/rnl and one patient each had basal 
cell carcinoma (5.2 ng/rnl), Bowen's disease (5.2 ng/rnl), mela-
noma (5.2 ng/ml), erythroderma (7.0 ng/rnl) and pemphigus 
vulgaris (5.2 ng/rnl). The remainder of the group had values 
below 5.0 ng/ml. 
Carcinoembryonic antigen levels were determined in 18 pa-
tients with EB (Table I). The 3 patients with dominant EB 
simplex had normal levels of CEA (2.B ± 0.5 ng/ml; mean ± 
SE). Siniilarly, patients with dominant dystrophic EB had 
normal levels of CEA (mean ± SE = 4.5 ± 1.0 ng/ml; p = NS) 
when compared to the dermatologic control group. Individually, 
only two of the seven patients with dominant dystrophic EB 
had levels above 5 ng/ml (7.B and 8.0 ng/ml), but these were 
both within the range of the dermatologic control group (Table 
1). 
In contrast to these fmdings were the striking increases in 
circulating CEA that were observed in patients with recessive 
dystrophic EB (Table I). As a group, patients with recessive 
dystrophic EB had an approximate 14-fold increase in CEA 
levels when compared to the dermatologic controls (p < 0.001). 
Within this group, heterogeneity in the values was observed 
with two patients (both mildly affected siblings) having normal 
levels, while the remainder had levels ranging up to 200 ng/rnl, 
a value representing an approximate 40-fold increase in CEA. 
Only two patients with recessive EB letalis were available for 
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study. One of these also had markedly increased CEA levels, 
but meaningful statistical analysis could not be performed due 
to the small number of patients. 
Since it seemed possible that the increased levels of CEA 
might in some way be reflective of disease activity, patients 
with the recessive forms of EB were ranked by clinical severity. 
As depicted in Table II, in every case the patients with the 
roost extensive blistering and severe debilitation were those 
with the highest CEA values. 
DISCUSSION 
The present study demonstrates that patients with recessive 
forms of EB, particularly recessive dystrophic EB, express the 
oncofetal glycoprotein, carcinoembryonic antigen. As a group 
there was a minimum 14-fold increase in circulating CEA levels, 
even when compared to the dermatologic control group which 
had slightly higher CEA levels than those reported in non-
diseased controls [4]. In this regard it is important to point out 
that, although some of the patients with certain cutaneous 
tuIDors had modest CEA elevations (e.g., mycosis fungoides), 
none had levels even approaching those seen in the severe cases 
of EB (Table II). 
The source of the CEA or CEA cross-reactive material is 
presently unknown. However, there was a general correlation 
between disease activity and CEA levels (Table II) and it is 
possible that the chronic ulcerative and reparative process in 
the skin has unmasked or permitted greater expression of CEA. 
Furthermore, since EB can involve the gastrointestinal tract 
[10, 11], it may be that this tissue contributes to the elevated 
CEA. This situation may be analogous to that observed by 
Hansen et al [4] in inflammatory bowel disease, although the 
levels in our patients greatly exceed those reported for ulcera-
tive colitis patients. 
An alternative, but not mutually exclusive possibility, is that 
the expression of elevated levels of CEA is genetically linked to 
certain forms of recessive EB or is part of a pleiotropic effect of 
the gene coding for recessive dystrophic EB. In this regard it is 
noteworthy that increased CEA has been observed in the cancer 
fanllly syndrome [12], hereditary adenomatosis [13] and eleva-
tions in CEA and a-fetoprotein, another oncofetal antigen, have 
been reported in the hereditary disorder, ataxia telangiectasia 
[14]. Although a-fetoprotein levels were completely normal in 
the plasma of all of the EB patients examined in this study 
TABLE I. L evels of circulating carcinoembryonic antigen (CEA) 
Disease Number CEA (ng/ ml) 
M ean ± SE Range 
Controls 
Normal, nonsmoking adults 38 0-5.0 
Nondermatologic patients" 54 0.2-3.6 
Dermatologic patients" 21 4.6 ± 0.4 0.8-8.8 
Epidermolysis bullosa 
Recessive dystrophicc 6 62.9 ± 31.5 2.8-200.0 
Recessive letalisd 2 ND 0.3-104.0 
Dominant dystrophicc 7 4.5 ± 1.0 0.8-8.0 
Dominant simplex' 3 2.8 ± 0.5 2.0-3.6 
a Patients with juvenile rheumatoid arthritis or renal disease. 
b Represents 6 patients with mycosis fungo ides and/ or Sezary syn-
drome, 3 each with melanoma and basal cell carcinoma, 2 each with 
pemphigoid and actinic keratosis and 1 each with pemphigus vulgaris, 
erythroderma, Bowen's disease, Kaposi's sarcoma and immunoblastic 
lyznphadenopathy. 
c p < 0.001 compared to the dermatologic patient group. 
d Meaningful statistics not possible due to the small number of 
patients. 
e p = NS compared to the dermatologic patient group. 
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TABLE II. Comparison of clinical severity of epidermolysis bullosa 
(EB) with circulating carcinoembryonic antigen (CEA) activity 
Patient Sex Age Severity" CEA (ng/ml) 
Recessive dystrophic EB 
P .T ." M 23 1+ 2.8 
S.A." F 29 1+ 5.6 
R.C. M 9 3+ 29.0 
S.H. F 17 4+ 200.0 
T .H. F 4 4+ 32.0 
M.S. M 3 4+ 108.0 
Recessive EB letalis 
J.C. F 35 1+ 0.3 
J .H . M 16 4+ 104.0 
" Semiquantitative estimate of severity; 1 +, mild; 2+, mild-moderate; 
3+, moderate-severe; 4+, severe. 
"P.T. and S.A. are siblings. 
(unpublished observation), it has been suggested that overpro-
duction of a structurally altered collagenase in cell cultures is 
genetically specific for recessive dystrophic EB [15, 16]. The 
possibility that the expression of increased CEA activity is an 
additional genetically associated finding in the disease should 
be further explored. 
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